Merck Serono strikes mega CAR-T therapy deal with Intrexon
Enlarge image


Merck Serono strikes mega CAR-T therapy deal with Intrexon

31.03.2015 - Merck Serono has forged a US$941m (€876m) deal with US Intrexon for the development and commercialisation of CAR-T therapies. The new CAR-T projects are set to strengthen their R&D technology portfolio in immuno-oncology.

Under the terms of the agreement, Merck Serono, which is the R&D arm of Merck KGaA will hand over a US$115m (€107m) upfront payment to Intrexon together with a commitment of up to US$826m (€770m) in milestones for the first two targets. Merck will later select these targets. Intrexon is also eligible to receive tiered royalties on product sales. In exchange, Merck will have exclusive access to the Virginia-based firm’s Chimeric Antigen Receptor T-cell (CAR-T) technology platform. Shares of Intrexon, which until now had a market cap of almost US$5bn, have shot up by 9% since the announcement of the deal.

The collaboration accelerates Merck Serono’s strategy to develop innovative therapies that modulate the immune system’s natural ability to fight tumours. CAR-T cells are genetically engineered T-cells with synthetic receptors that recognise a specific antigen expressed on tumour cells. When CAR-T binds to a target, an immunological attack against the cancer cells is triggered.

CAR-T is a recent breakthrough technology in immuno-oncology. Since companies like Novartis and Juno Therapeutics championed the therapy showing how it could offer major new advances in cancer patients, the technology has taken the biopharma world by storm.

The Merck-Intrexon collaboration will utilise Intrexon’s cell engineering techniques and its RheoSwitch gene regulation platform by aiming to develop products that empower the immune system in a regulated manner to overcome the current challenges of CAR-T therapy. Synthetic biology firm Intrexon collaborates with companies in the health, food, energy, environment and consumer sectors.


Stock MarketsFranceEU

27.03.2015 Europe is once more proving that it can be a good bet for biotech companies going public. A newly established EU-wide lobbying initiative could help the IPO boom on its way.


24.03.2015 Poland has announced the closing of a new venture capital fund at US$42m (€32m). The fund, which is the first of its kind in Poland, is dedicated to the Life Sciences with a strong connection to Central and Eastern Europe.


23.03.2015 A BASF-led consortium aims to decrease bio-based production costs using industrial biotechnology. The Horizon2020 funded consortium is the sixth project of the SPIRE Public Private Partnership and has a budget of €14m.

Stock MarketsFranceSwedenUKNorwayIreland

20.03.2015 There are no signs of inertia creeping into the European biotech industry this spring. A total of eight IPOs are set to go public by the end of the year’s first quarter.


17.03.2015 Pharma giants GlaxoSmithKline (GSK) and Johnson & Johnson (J&J) will be key collaborators in a new global fund for dementia research to address the rising threat posed by dementia and Alzheimer’s disease.


19.03.2015 French venture capital firm Seventure Partners has raised a further €25m for its microbiome-focused Health for Life Capital Fund. It now stands at €100m.


12.03.2015 With around 1,400 companies and 2,400 participants, the springtime counterpart of BIO-Europe enjoyed a successful premiere in France this year. The overall mood of the European biotech industry was positive, and the French hosts in particular reported new initiatives.


11.03.2015 Belgian cell-based therapeutics developer and CMO MaSTherCell SA has been acquired by US biotech Orgenesis Inc. for €23m.


10.03.2015 The Gates Foundation has dipped into its purse to bring infectious diseases vaccines to the poorest countries. German vaccine specialist CureVac is set to receive US$52m for their mRNA platform technology.

© 2007-2015 BIOCOM


All Events

Current issue

All issues

Product of the week


Stock list

All quotes


  • MEDIGENE12.51 EUR18.92%
  • CO.DON2.88 EUR9.09%
  • FORMYCON26.77 EUR8.91%


  • 4SC1.16 EUR-7.20%
  • MOLOGEN5.69 EUR-2.07%
  • CYTOS1.43 CHF-1.38%


  • CYTOS1.43 CHF320.6%
  • MEDIGENE12.51 EUR194.4%
  • FORMYCON26.77 EUR60.3%


  • MORPHOSYS60.10 EUR-19.6%
  • BASILEA108.20 CHF-11.5%
  • WILEX3.10 EUR-9.6%


  • SANTHERA96.50 CHF2312.5%
  • FORMYCON26.77 EUR271.8%
  • WILEX3.10 EUR198.1%


  • CYTOS1.43 CHF-52.5%
  • MOLOGEN5.69 EUR-49.4%
  • PAION2.53 EUR-24.0%

No liability assumed, Date: 30.03.2015